PROJECT STAGE
Therapeutic area
Neuropathic Pain
Background info
Indication
Advantages
Intellectual property
Owner/lead
Project Aim
To develop an agonist of Galanin Receptor 2 (GalR2) for the treatment of pain
Advantage
Potential to address current unmet need in chronic pain with an improved side-effect profile to current therapies
Target Class
G-Protein Coupled Receptor (GPCR)
Modality
Biotherapeutic agent
Current Status
Discovery with in-vivo proof of efficacy
Intellectual Property
Opportunity to create a protective IPR portfolio
Offering
Licence or collaboration for pre-clinical / clinical development